Introduction {#sec1}
============

Anastomotic leakage (AL) continues to be the most difficult complication following low anterior resection. The range of leakage can vary from 3% to 19% of rectal resection, depending on the type of operation and patient \[[@cit0001]--[@cit0004]\]. An early diagnosis of AL, before the patient develops serious complications, can minimize morbidity and mortality \[[@cit0005], [@cit0006]\]. Nonetheless, identification of dehiscence is often difficult and delayed to the point where the patient's well-being is already at risk.

Today, the diagnosis of AL relies on clinical assessment, biochemical markers, and imaging studies, which still may not provide all the information needed \[[@cit0007]\]. It is clear that the current means of AL diagnosis are not always satisfactory, thereby creating the need for newer, more effective methods to be researched and instituted.

The most commonly used method to identify AL is C-reactive protein (CRP) testing \[[@cit0008], [@cit0009]\]. It is a non-specific, acute phase reactant, released in response to inflammation. Its ability to aid early detection of AL has been well documented \[[@cit0009]\]. Two major drawbacks of CRP testing are the low specificity and low positive predictive values associated with the method. Persistent postoperative CRP increases can often be related to a number of complications that are not necessarily linked to AL.

Aim {#sec2}
===

In this study, the authors evaluated postoperative changes in serum concentration of 27 different cytokines following low anterior resection for rectal cancer, with the goal of finding new, early biomarkers of anastomotic leak.

Material and methods {#sec3}
====================

Study population {#sec3.1}
----------------

Patients enrolled in this study were recruited as part of a prospective, non-randomized study comparing inflammatory, immune, and angiogenic responses in colorectal patients following robotic and conventional surgery. It was conducted as part of the WROVASC -- Integrated Cardiovascular Center project. The study population consisted of 32 unselected patients with rectal adenocarcinoma (located within 12 cm of the anal verge), who underwent elective restorative rectal resection at the Regional Specialist Hospital, Wroclaw, Poland between 2013 and 2015. Exclusion criteria included patients under 18 years of age, emergency operations, advanced cancers that were not amenable to curative resection, immunosuppression, current steroid use, and patients with American Society of Anesthesiologists (ASA) physical status ≥ 4.

Preoperative workup included a physical examination, colonoscopy, magnetic resonance imaging (MRI) of the pelvis, computed tomography (CT), abdomen, pelvis and chest X-ray or chest CT. Patients with suspected nodal involvement and patients with T3 or T4 tumors underwent neo-adjuvant treatment. Patients were given the choice to undergo either open colorectal surgery (OCS) or robot-assisted colorectal surgery (RACS), after receiving detailed information from the operating surgeon as to the advantages and disadvantages of each technique.

The standard clinical pathway was applied to all patients. Everyone received intravenous antibiotic prophylaxis prior to incision. Postoperatively, oral liquids were permitted on postoperative day 1 and, if tolerated, advanced to liquid and solid diets on postoperative days 2 and 3. Nasogastric tubes were not inserted and surgical closed drains were removed on postoperative day 1. The criteria for discharge included tolerance of a soft diet and no patient complaints or reported complications.

Patient demographics, comorbidities, perioperative outcomes, and postoperative complications (up to 30 days after surgery) were recorded prospectively in the database. Anastomotic dehiscence was defined as "a communication between the intra- and extraluminal compartments, owing to a defect of the integrity of the intestinal wall at the anastomosis between the colon and rectum or the colon and anus" in accordance with the International Study Group of Rectal Cancer \[[@cit0010]\]. Blood samples from patients were collected prior to surgery and at postoperative day 3, prior to any clinical manifestation of AL. The study protocol was approved by the Medical Ethics Committees of the Regional Specialist Hospital. Informed consent was obtained from all patients.

Analytical methods {#sec3.2}
------------------

Blood was drawn by venipuncture, allowed to clot for 30 minutes, and then centrifuged (15 min, 720×g). Sera were collected, aliquoted, and kept frozen at --80° until examination. The concentrations of 27 cytokines were measured and included: IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, interferon (IFN)-γ, IFN-γ-inducible protein (IP)-10, eotaxin-1, FGF-2, G-CSF, granulocyte-monocyte colony-stimulating factor (GM-CSF), monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1α and -1β, regulated on activation, normal T-cell expressed and secreted (RANTES), tumor necrosis factor (TNF)-α, vascular endothelial growth factor (VEGF)-A, and platelet-derived growth factor (PDGF)-BB. Measurements were performed in duplicate, according to the manufacturer's instructions, using the BioPlex 200 System (Bio-Rad, Hercules CA). The system uses a flow cytometry-based method utilizing magnetic microspheres conjugated with monoclonal antibodies (Luminex xMAP technology) for simultaneous determination of analytes. Standard curves and concentrations were calculated using Bioplex Manager 6.0 software (Bio-Rad) and based on the five-parameter logistic plot regression formula. Finally, hs-CRP was measured using the Multigent CRP Vario immunoturbidimetric test with the Architect 4100 Ci analyzer (Abbott Laboratories, Lake Bluff IL).

Statistical analysis {#sec3.3}
--------------------

Data distribution was tested using the Kolmogorov-Smirnov test for normality and equality of variances using the *F*-test. Data were analyzed using the *t*-test for independent samples with Welch correction when necessary or the Mann-Whitney *U* test, and presented, respectively, as means with 95% confidence interval (CI) or medians with interquartile range. The predictive power of cytokines was assessed using ROC analysis. Overall performance was determined in terms of area under the ROC curve (AUC) with the 95% CI. The AUC values were interpreted as follows: excellent (AUC ≥ 0.91), good (AUC: 0.81--0.90), fair (AUC: 0.71--0.80), poor (AUC: 0.50--0.70). Sensitivity and specificity of potential markers at the optimal cut-off value (based on the Youden index), as well as likelihood ratios and predictive values for assumed 9.6% prevalence of anastomotic leak \[[@cit0008]\], were also calculated.

In order to examine the effect of AL and other factors on potential biomarkers, analysis of covariance (ANCOVA) was applied. All calculated probabilities were two-tailed and *p-*values ≤ 0.05 were considered statistically significant. The statistical analysis was conducted using MedCalc Statistical Software version 16.8 (MedCalc Software bvba, Ostend, Belgium; <https://www.medcalc.org>; 2016). Relative changes (increases/decreases) on postoperative day 3, as compared to baseline preoperative levels, were measured and expressed as fold increase (denoted as Δ~POD3~).

Results {#sec4}
=======

A total of 32 patients with rectal cancer undergoing restorative rectal resection were enrolled in the study. Of these, 18 patients underwent open rectal resection and 14 had the robot-assisted procedure. Demographic and perioperative data are shown in [Table I](#t0001){ref-type="table"}. A total of 17 (53%) patients underwent neoadjuvant treatment and 13 (41%) patients received a defunctioning stoma. Five (15.2%) patients developed anastomotic leak. Anastomotic leaks were diagnosed between postoperative days 3 and 12. All required reoperation.

###### 

Characteristics of rectal cancer (RC) patients

  Parameter                              RC patients without leak   RC patients with leak   Probability, *p*
  -------------------------------------- -------------------------- ----------------------- ------------------------------------------
  Age, mean ± SD \[years\]               69.8 ±8.3                  66.4 ±10                0.425[^t^](#tf1-1){ref-type="table-fn"}
  Sex, F/M                               10/17                      2/3                     1[^F^](#tf1-2){ref-type="table-fn"}
  Stage, TNM^7th^: 0/I/II/III/IV         0/3/11/13/0                1/1/2/1/0               0.092[^χ2^](#tf1-3){ref-type="table-fn"}
  Stage T: Tis/1/2/3/4                   0/0/5/17/5                 1/0/1/3/0               0.096[^χ2^](#tf1-3){ref-type="table-fn"}
  Stage N: 0/1/2                         14/6/7                     4/0/1                   0.414[^χ2^](#tf1-3){ref-type="table-fn"}
  Stage G: 1/2/3\*                       4/20/3                     2/3/0                   0.350[^χ2^](#tf1-3){ref-type="table-fn"}
  ASA                                    5/14/8                     1/4/0                   0.353[^χ2^](#tf1-3){ref-type="table-fn"}
  Length of surgery \[min\], mean ± SD   205.5 ±74                  182 ±89                 0.539[^t^](#tf1-1){ref-type="table-fn"}
  Harvested lymph nodes, *n* (range)     14 (3--22)                 12 (3--22)              0.308[^M^](#tf1-4){ref-type="table-fn"}

-- t-test for independent samples

-- Fisher's exact test

-- chi-square test

-- Mann-Whitney U test.

Cytokine concentrations {#sec4.1}
-----------------------

Of the 27 cytokines measured, the levels of IL-2, IL-15, and IL-17 were all below the lower limit of detection in the majority of samples assessed. As a result, they were dropped from further analysis.

On postoperative day 3, there were differences in the concentrations of IL-6, hs-CRP, IL-9, RANTES and FGF2. Interestingly, while hs-CRP, IL-6, and RANTES were significantly higher in patients with a leak, the concentrations of IL-9 and FGF2 were significantly lower ([Table II](#t0002){ref-type="table"}).

###### 

Comparison of serum cytokine concentrations at postoperative day 3 (POD3) in patients with and without anastomotic leak

  Cytokines (POD3)               Without leak           With leak              *P*-value
  ------------------------------ ---------------------- ---------------------- --------------------------------------------
  Inflammatory mediators:                                                      
   IL-1β                         2.05 (1.6--2.7)        1.54 (0.5--4.6)        0.420[^t^](#tf2-1){ref-type="table-fn"}
   IL-1ra                        133.8 (103--174)       152.2 (23--1013)       0.741[^t^](#tf2-1){ref-type="table-fn"}
   IL-6                          42.6 (25.2--72.1)      227.7 (19--2662)       0.024[^t^](#tf2-1){ref-type="table-fn"}
   TNF-α                         30.8 (24.5--38.8)      22.8 (9.4--55.7)       0.326[^t^](#tf2-1){ref-type="table-fn"}
   hs-CRP                        107.9 (84.7--137.4)    314.8 (240.8--411.5)   \< 0.001[^t^](#tf2-1){ref-type="table-fn"}
  Th1/Th2/Th9 immune response:                                                 
   IL-4                          4.53 (3.19--5.75)      4.31 (2.67--7.98)      0.850[^M^](#tf2-2){ref-type="table-fn"}
   IL-5                          5.93 (2.7--9.2)        1.78 (0.31--5.87)      0.310[^t^](#tf2-1){ref-type="table-fn"}
   IL-7                          9.08 (6.44--17.57)     8.89 (6.1--12.24)      0.527[^M^](#tf2-2){ref-type="table-fn"}
   IL-9                          16.15 (13.1--20)       7.17 (2.1--24.2)       0.011[^t^](#tf2-1){ref-type="table-fn"}
   IL-10                         12.53 (7.9--19.9)      12.67 (1.06--151.9)    0.987[^t^](#tf2-1){ref-type="table-fn"}
   IL-12 (p70)                   64.2 (45.8--90)        41.1 (12.1--140)       0.318[^t^](#tf2-1){ref-type="table-fn"}
   IL-13                         10.5 (7.98--14.9)      7.2 (3.5--14.9)        0.281[^t^](#tf2-1){ref-type="table-fn"}
   IFN-γ                         49.8 (38--65.1)        49.9 (20.6--120.7)     0.993[^t^](#tf2-1){ref-type="table-fn"}
  Chemokines:                                                                  
   Eotaxin-1                     60 (45.2--79.6)        45.2 (15.2--134.2)     0.450[^t^](#tf2-1){ref-type="table-fn"}
   IP-10                         940 (688--1283)        842 (253--2798)        0.789[^t^](#tf2-1){ref-type="table-fn"}
   IL-8                          29 (22.4--63.6)        42.1 (25--126)         0.704[^M^](#tf2-2){ref-type="table-fn"}
   MCP-1                         59.9 (39--183.3)       131.3 (65.1--346.5)    0.255[^M^](#tf2-2){ref-type="table-fn"}
   MIP-1α                        3.62 (2.88--4.55)      2.71 (0.76--9.59)      0.364[^t^](#tf2-1){ref-type="table-fn"}
   MIP-1β                        56.3 (43--73.6)        54.9 (7.8--386.4)      0.951[^t^](#tf2-1){ref-type="table-fn"}
   RANTES                        2710 (2119--3465)      6561 (1410--30526)     0.017[^t^](#tf2-1){ref-type="table-fn"}
  Growth factors:                                                              
   FGF2                          23.4 (17.5--31.3)      9.5 (3.82--23.6)       0.023[^t^](#tf2-1){ref-type="table-fn"}
   G-CSF                         83.6 (68.2--102.6)     102.2 (25.9--404.1)    0.502[^t^](#tf2-1){ref-type="table-fn"}
   GM-CSF                        26.8 (21.6--33.4)      30.8 (15.5--61.3)      0.618[^t^](#tf2-1){ref-type="table-fn"}
   PDGF-BB                       1520 (1129--2046)      1438 (732--2824)       0.883[^t^](#tf2-1){ref-type="table-fn"}
   VEGF-A                        151.1 (109.5--208.6)   150.4 (69--327.8)      0.991[^t^](#tf2-1){ref-type="table-fn"}

-- t-test for independent samples

-- Mann-Whitney U test. Data presented as mean with 95% CI or medians with interquartile range. All concentrations were measured in pg/ml, except for hs-CRP presented in mg/l.

Relative changes in cytokine levels {#sec4.2}
-----------------------------------

Changes in cytokine concentrations on postoperative day 3 were also compared to baseline preoperative levels. There were significantly more pronounced increases in IL-6 and G-CSF in patients with AL ([Table III](#t0003){ref-type="table"}).

###### 

Comparison of relative changes in serum cytokine concentrations at POD3 (Δ~POD3~) as compared to cytokine baseline levels in rectal cancer patients without and with anastomotic leak

  Cytokines (Δ~POD3~)            Without leak        With leak            *P*-value
  ------------------------------ ------------------- -------------------- -----------------------------------------
  Inflammatory mediators:                                                 
   IL-1β                         1.26 (0.8--1.6)     1.48 (0.88--2.58)    0.613[^M^](#tf3-2){ref-type="table-fn"}
   IL-1ra                        1.22 (0.95--1.57)   1.82 (0.22--15.2)    0.596[^t^](#tf3-1){ref-type="table-fn"}
   IL-6                          3.1 (1.6--7.1)      20.8 (7.3--22.1)     0.019[^M^](#tf3-2){ref-type="table-fn"}
   TNF-α                         1.15 (0.96--1.37)   1.1 (0.38--3.21)     0.864[^t^](#tf3-1){ref-type="table-fn"}
  hs-CRP                         23.8 (17.4--32.5)   87.1 (10.5--72.1)    0.170[^t^](#tf3-1){ref-type="table-fn"}
  Th1/Th2/Th9 immune response:                                            
   IL-4                          1.05 (0.86--1.29)   1 (0.5--2)           0.855[^t^](#tf3-1){ref-type="table-fn"}
   IL-5                          1.26 (0.95--1.67)   0.69 (0.14--3.48)    0.133[^t^](#tf3-1){ref-type="table-fn"}
   IL-7                          1.26 (0.98--1.61)   1.39 (0.25--7.87)    0.778[^t^](#tf3-1){ref-type="table-fn"}
   IL-9                          1.16 (0.92--1.47)   1.36 (0.36--5.09)    0.634[^t^](#tf3-1){ref-type="table-fn"}
   IL-10                         1.41 (0.81--2.45)   2.2 (0.29--16.6)     0.531[^t^](#tf3-1){ref-type="table-fn"}
   IL-12 (p70)                   1.42(1.13--1.97)    1.69 (0.95--2.39)    0.850[^M^](#tf3-2){ref-type="table-fn"}
   IL-13                         1.06 (0.84--1.34)   0.77 (0.33--1.81)    0.283[^t^](#tf3-1){ref-type="table-fn"}
   IFN-γ                         1.01 (0.83--1.23)   1.06 (0.31--3.58)    0.857[^t^](#tf3-1){ref-type="table-fn"}
  Chemokines:                                                             
   Eotaxin-1                     0.81 (0.70--0.93)   0.75 (0.29--1.93)    0.706[^t^](#tf3-1){ref-type="table-fn"}
   IP-10                         0.73 (0.54--1.01)   1.04 (0.45--2.4)     0.386[^t^](#tf3-1){ref-type="table-fn"}
   IL-8                          1.09 (0.73--1.71)   4.16 (1.53--12.93)   0.100[^M^](#tf3-2){ref-type="table-fn"}
   MCP-1                         0.97 (0.72--1.8)    2.89 (1.69--10.56)   0.076[^M^](#tf3-2){ref-type="table-fn"}
   MIP-1α                        1.11 (0.86--1.42)   2.09 (0.91--3.21)    0.237[^M^](#tf3-2){ref-type="table-fn"}
   MIP-1β                        0.94 (0.73--1.2)    1.44 (0.37--5.63)    0.212[^t^](#tf3-1){ref-type="table-fn"}
   RANTES                        0.78 (0.51--1.2)    1.04 (0.34--2.99)    0.609[^t^](#tf3-1){ref-type="table-fn"}
  Growth factors:                                                         
   FGF2                          1.03 (0.82--1.28)   1.02 (0.14--7.21)    0.989[^t^](#tf3-1){ref-type="table-fn"}
   G-CSF                         1.11 (0.87--1.42)   2.27 (0.51--10)      0.046[^t^](#tf3-1){ref-type="table-fn"}
   GM-CSF                        1.05 (0.89--1.22)   1.31 (0.41--4.2)     0.589[^t^](#tf3-1){ref-type="table-fn"}
   PDGF-BB                       0.90 (0.71--1.14)   0.77 (0.29--2.02)    0.617[^t^](#tf3-1){ref-type="table-fn"}
   VEGF-A                        1.75 (1.26--2.45)   1.8 (0.23--13.8)     0.958[^t^](#tf3-1){ref-type="table-fn"}

-- t-test for independent samples

-- Mann-Whitney U test. Data presented as mean (95% CI) or median (IQR) relative changes (fold increase at a given time point as compared to cytokine preoperative level).

Predictive power of cytokines as AL markers {#sec4.3}
-------------------------------------------

A ROC analysis was used to evaluate the power of cytokines as potential AL markers. Only cytokines, which differed significantly at postoperative day 3 were analyzed. Of these, overall performance of hs-CRP was found to be excellent while ΔIL-6, IL-6, RANTES, and FGF2 were all identified as good, and ΔG-CSF and IL-9 were devoid of predictive power ([Figure 1](#f0001){ref-type="fig"}). Additionally, specificity, likelihood ratios and predictive power of hs-CRP were superior to other markers ([Table IV](#t0004){ref-type="table"}).

###### 

Discriminative power of analyzed cytokines as markers of anastomotic leak

  Marker         AUC (95% CI), *p*              Cut-off[^1^](#tf4-1){ref-type="table-fn"}   Sens. and Spec.   LR+ and LR--   +PV and --PV[^2^](#tf4-2){ref-type="table-fn"}
  -------------- ------------------------------ ------------------------------------------- ----------------- -------------- ------------------------------------------------
  hs-CRP~POD3~   0.99 (0.86--1), \< 0.0001      \> 203.8 mg/l                               100% and 92.3%    13 and 0       58 and 100
  RANTES~POD3~   0.81 (0.62--0.93), 0.007       \> 3689 pg/ml                               75% and 80%       3.75 and 0.3   28.5 and 97
  IL-6~POD3~     0.82 (0.63--0.94), \< 0.001    \> 65.9 pg/ml                               100% and 76%      4.2 and 0      31 and 100
  FGF2~POD3~     0.86 (0.68--0.96), \< 0.0001   ≤ 17.4 pg/ml                                100% and 68%      3.1 and 0      25 and 100
  IL-9~POD3~     0.82 (0.63--0.94), 0.078       ≤ 6.8 pg/ml                                 75% and 100%      -- and 0.25    100 and 97
  ΔG-CSF~POD3~   0.75 (0.56--0.89), 0.213       \> 1.9                                      75% and 88%       6.2 and 0.3    40 and 97
  ΔIL-6~POD3~    0.87 (0.69--0.97), \< 0.0001   \> 4.9                                      100% and 68%      3.1 and 0      25 and 100

In case of relative changes (Δ) cut-off value is a fold increase at a given time point compared to cytokine baseline (preoperative) level;

prevalence of the leak following colorectal surgery was estimated to be 9.6% \[[@cit0008]\].

![ROC curves of cytokines with a potential as AL markers (hsCRP (**A**), IL-6 (**B**), RANTES (**C**), IL-9 (**D**), FGF2 (**E**), DG-CSF (**F**), (DIL-6 (**G**))](WIITM-13-31508-g001){#f0001}

Factors affecting prospective biomarkers of AL {#sec4.4}
----------------------------------------------

In order to test whether an elevation in the prospective biomarker at postoperative day 3 can be attributed solely to AL, the authors examined the effect of AL and cancer-related (tumor grade and cancer stage N and T), patient-related (patient's physical status -- ASA grade), and surgery-related factors (type of surgery, length and extent of surgery) using ANCOVA.

The concentrations of hs-CRP at postoperative day 3 were affected not only by AL but also by cancer-related factors such as tumor grade and depth of invasion (T stage). These seemed also to be affected by patient's physical status, which was determined using the ASA physical status classification system, as well as by the type of surgical procedure performed (open or minimally invasive). However, no statistical significance was reached. The concentrations of IL-6 on postoperative day 3 were significantly affected by tumor grade, depth of invasion (stage T), and type of surgery. RANTES was significantly affected by the extent of surgery as measured by the number of lymph nodes harvested. FGF2 seemed to be affected by tumor grade, although the statistical significance was not reached. Relative change in IL-6 (ΔIL-6~POD3~) was the only prospective biomarker of AL that was not affected by factors related to cancer, the patient, or type of surgery ([Table V](#t0005){ref-type="table"}).

###### 

Significance of the effect exerted by cancer-, patient- or surgery-related factors on the prospective AL biomarkers when examined with AL using analysis of covariance (ANCOVA)

  -------------------------------------------------------------------------------------------------------------------------------
  Covariates                      CRP~(POD3)~         IL-6~(POD3)~       FGF2~(POD3)~       RANTES~(POD3)~     ΔIL-6~(POD3)~
  ------------------------------- ------------------- ------------------ ------------------ ------------------ ------------------
  Cancer-related factors:                                                                                      

   AL and tumor grade (G)         AL: *p* = 0.001\    AL: *p* = 0.007\   AL: *p* = 0.006\   AL: *p* = 0.031\   AL: *p* = 0.006\
                                  G: *p* = 0.020      G: *p* = 0.033     G: *p* = 0.082     G: *p* = 0.668     G: *p* = 0.173

   AL and stage N (N)             AL: *p* \< 0.001\   AL: *p* = 0.006\   AL: *p* = 0.020\   AL: *p* = 0.028\   AL: *p* = 0.006\
                                  N: *p* = 0.777      N: *p* = 0.180     N: *p* = 0.376     N: *p* = 0.804     N: *p* = 0.465

   AL and stage T (T)             AL: *p* \< 0.00\    AL: *p* = 0.003\   AL: *p* = 0.031\   AL: *p* = 0.066\   AL: *p* = 0.003\
                                  T: *p* = 0.034      T: *p* = 0.084     T: *p* = 0.631     T: *p* = 0.337     T: *p* = 0.146

  Patient-related factors:                                                                                     

   AL and ASA (A)                 AL: *p* \< 0.001\   AL: *p* = 0.010\   AL: *p* = 0.040\   AL: *p* = 0.019\   AL: *p* = 0.005\
                                  A: *p* = 0.073      A: *p* = 0.328     A: *p* = 0.591     A: *p* = 0.872     A: *p* = 0.306

  Surgery-related factors:                                                                                     

   AL and type of surgery (S)     AL: *p* = 0.001\    AL: *p* = 0.124\   AL: *p* = 0.034\   AL: *p* = 0.015\   AL: *p* = 0.037\
                                  S: *p* = 0.095      S: *p* = 0.083     S: *p* = 0.896     S: *p* = 0.449     S: *p* = 0.144

   AL and length of surgery (L)   AL: *p* \< 0.001\   AL: *p* = 0.038\   AL: *p* = 0.013\   AL: *p* = 0.009\   AL: *p* = 0.019\
                                  L: *p* = 0.366      L: *p* = 0.746     L: *p* = 0.211     L: *p* = 0.199     L: *p* = 0.649

   AL and extent of surgery (E)   AL: *p* \< 0.001\   AL: *p* = 0.018\   AL: *p* = 0.039\   AL: *p* = 0.025\   AL: *p* = 0.012\
                                  E: *p* = 0.994      E: *p* = 0.895     E: *p* = 0.548     E: *p* = 0.036     E: *p* = 0.334
  -------------------------------------------------------------------------------------------------------------------------------

Preoperative concentrations of cytokines and AL {#sec4.5}
-----------------------------------------------

The authors also compared preoperative concentration of cytokines in patients who did and did not develop AL in the perioperative period ([Table VI](#t0006){ref-type="table"}). Patients who developed AL were characterized by significantly lower baseline levels of MCP-1, MIP-1α, IL-8, FGF2, and G-CSF.

###### 

Comparison of preoperative serum cytokine concentrations in patients with and without anastomotic leak

  Cytokines (preoperative)       Without leak        With leak             *P*-value
  ------------------------------ ------------------- --------------------- -----------------------------------------
  Inflammatory mediators:                                                  
   IL-1β                         1.68 (1.3--2.1)     1.11 (0.6--2.2)       0.140[^t^](#tf6-1){ref-type="table-fn"}
   IL-1ra                        114.5 (91.8--143)   78.6 (22.3--276)      0.239[^t^](#tf6-1){ref-type="table-fn"}
   IL-6                          13.1 (9.1--19)      18.1 (4.1--16)        0.286[^t^](#tf6-1){ref-type="table-fn"}
   TNF-α                         28.4 (23.6--34.3)   20.7 (14.1--30.4)     0.172[^t^](#tf6-1){ref-type="table-fn"}
   hs-CRP                        4.01 (2.8--5.8)     3.6 (0.4--30.8)       0.902[^W^](#tf6-3){ref-type="table-fn"}
  Th1/Th2/Th9 immune response:                                             
   IL-4                          4.49 (3.4--7.2)     3.58 (2.7--11.9)      0.670[^M^](#tf6-2){ref-type="table-fn"}
   IL-5                          2.86 (1.9--4.2)     1.27 (0.4--4.3)       0.109[^t^](#tf6-1){ref-type="table-fn"}
   IL-7                          9.08 (7.1--11.6)    6.15 (2.7--14.1)      0.216[^t^](#tf6-1){ref-type="table-fn"}
   IL-9                          14.5 (11.2--18.7)   8.06 (2--32)          0.109[^t^](#tf6-1){ref-type="table-fn"}
   IL-10                         8.79 (6.6--11.7)    7.09 (1.3--39.6)      0.752[^W^](#tf6-3){ref-type="table-fn"}
   IL-12 (p70)                   41.8 (31.3--55.7)   34.1 (11.3--102)      0.588[^t^](#tf6-1){ref-type="table-fn"}
   IL-13                         10.6 (8--14.2)      9.8 (4.2--22.7)       0.811[^t^](#tf6-1){ref-type="table-fn"}
   IFN-γ                         52.7 (41.7--66.5)   49.8 (21.3--117)      0.853[^t^](#tf6-1){ref-type="table-fn"}
  Chemokines:                                                              
   Eotaxin-1                     74.9 (57.8--97.1)   56.7 (30.9--104)      0.382[^t^](#tf6-1){ref-type="table-fn"}
   IP-10                         1213 (948--1552)    1087 (361--3271)      0.740[^t^](#tf6-1){ref-type="table-fn"}
   IL-8                          37.1 (26.3--52.2)   12.3 (8.1--18.9)      0.010[^t^](#tf6-1){ref-type="table-fn"}
   MCP-1                         77.9 (60.4--100)    38.3 (18.6--79)       0.031[^t^](#tf6-1){ref-type="table-fn"}
   MIP-1α                        2.96 (2.52--3.65)   1.85 (1.53--2.36)     0.012[^M^](#tf6-2){ref-type="table-fn"}
   MIP-1β                        60.7 (44.8--82.2)   39.6 (19--82.7)       0.257[^t^](#tf6-1){ref-type="table-fn"}
   RANTES                        3417 (1881--5093)   13090 (2064--20669)   0.192[^t^](#tf6-1){ref-type="table-fn"}
  Growth factors:                                                          
   FGF2                          23.5 (17.6--31.3)   10 (4.3--23.2)        0.023[^t^](#tf6-1){ref-type="table-fn"}
   G-CSF                         73 (58.8--85.2)     46.8 (33.4--65.4)     0.027[^M^](#tf6-2){ref-type="table-fn"}
   GM-CSF                        26.9 (22.1--32.7)   23.8 (11.4--49.9)     0.633[^t^](#tf6-1){ref-type="table-fn"}
   PDGF-BB                       1854 (1389--2473)   1832 (902--3720)      0.973[^t^](#tf6-1){ref-type="table-fn"}
   VEGF-A                        92.7 (64.9--133)    78.3 (32.6--188)      0.697[^t^](#tf6-1){ref-type="table-fn"}

-- t-test for independent samples

-- Mann-Whitney U test

-- t-test with Welch correction. Data presented as mean with 95% CI or medians with interquartile range. All concentrations were measured in pg/ml, except for hs-CRP presented in mg/l.

Discussion {#sec5}
==========

Anastomotic leaks prolong hospital stay, increase morbidity, and contribute to one third of all postoperative deaths following colorectal surgery \[[@cit0011]\]. Because early leaks frequently cause only subtle and insidious symptoms, detection can often be difficult, even for the experienced surgeon \[[@cit0006], [@cit0012]\]. Compounding this is the fact that current diagnostic tests are frequently inadequate \[[@cit0007]\]. This includes CT scanning and contrast studies, which have limited accuracy when used for early detection \[[@cit0013]\].

When considering serum biomarkers, CRP is the most common marker used to predict AL \[[@cit0014]\]. In fact, it has proven to be a useful negative predictive test for AL on postoperative days 3--5 following colorectal surgery \[[@cit0008], [@cit0009], [@cit0015], [@cit0016]\]. Still, the downsides of CRP testing are its limited sensitivity (70%), specificity (76%), and low positive predictive value (16%), as they relate to AL \[[@cit0017]\].

Another marker used as a leak predictor is procalcitonin (PCT). This is believed to have a high specificity when detecting bacterial infection, and was initially used in intensive care units to monitor treatment of sepsis \[[@cit0018]\]. More recently, PCT has been used as a leak predictor. Its advantage over CRP is not yet clear. Lagoutte *et al.* evaluated leak markers between postoperative days 1 and 4 in a group of 100 colorectal patients \[[@cit0019]\]. They found PCT to be less accurate than CRP in detecting AL. Conversely, two more recent studies with larger cohorts demonstrated that PCT on postoperative day 5 had similar or better accuracy than CRP \[[@cit0020]\].

Recently, researchers have proposed evaluation of the peritoneal fluid cytokines for early detection of AL \[[@cit0021]\]. They theorize that local inflammation at the site of the anastomosis occurs before the first systemic symptoms of sepsis. In line with this is the concept that cytokines measured locally, in the proximity of anastomosis, can provide real-time information on its healing. Several studies have explored this hypothesis and have shown that levels of TNF, IL-1β, IL-6, and IL-10 in drain fluid were significantly higher in patients with AL \[[@cit0022]--[@cit0025]\]. Furthermore, the difference in cytokine levels between patients with AL and those without AL has been observed as early as postoperative day 1.

These early data are promising, although not solid. There is a lack of information on diagnostic sensitivity and specificity of peritoneal cytokines and, in most reports, their diagnostic accuracy was low. This concept also appears to have stalled in the current era of enhanced recovery programs, in which abdominal drains are not recommended \[[@cit0026], [@cit0027]\].

Being aware that CRP is not the primary mediator of inflammation, the authors made the decision to analyze mediators upstream to CRP in the inflammatory cascade and to evaluate inflammatory and immune mediators circulating in the peripheral blood, in search of novel AL markers.

To date, only a few reports have studied the relation between postoperative concentrations of systemic cytokines and AL. In 2014, Ellebaek *et al.* evaluated 10 different serum cytokines in the postoperative period and observed a significant increase of IL-1β, IL-4, IL-6, IL-8, and IL-10 on postoperative days 1-5 in patients with an early leak \[[@cit0028]\]. Reisinger *et al.* analyzed serum inflammation markers (CRP, calprotectin, IL-6) and intestinal damage markers in patients undergoing colorectal resection \[[@cit0029]\]. They found that CRP and calprotectin (a neutrophil activation product) showed not only high sensitivity (100%), but also high specificity (89%) during AL testing on postoperative day 3.

In the present study, of the 27 parameters analyzed on postoperative day 3, IL-6, hs-CRP, IL-9, RANTES, and FGF2 differed significantly between patients with and without AL. The ROC curve analysis revealed good diagnostic accuracy of IL-6, RANTES, and FGF2 for AL, but none were superior to hs-CRP. In fact, when compared with other analyzed parameters on postoperative day 3, hs-CRP had the highest sensitivity (100%) and the highest specificity (92%). As is evident from these results, hs-CRP continues to be the single most accurate serum biomarker of AL.

It is important to note that AL is not the sole factor affecting hs-CRP and cytokine concentrations in the perioperative period. Preoperative factors, including tumor grade, stage of neoplastic disease, and the patient's general state of health, might also influence cytokine concentrations at baseline \[[@cit0030], [@cit0031]\]. This, in turn, will have an impact on postoperative levels. Thus, if not addressed, the tumor- or patient-related factors may contribute to higher levels of cytokines and CRP, subsequently leading to false positive suspicion of AL. In this context, analysis of relative changes in the concentrations of biomarkers at postoperative day 3, in relation to their baseline preoperative levels, appears to be preferred, as it permits elimination of the effect of pre-surgical factors. As seen from this study, changes in IL-6, but not hs-CRP, were indicative of AL. Unlike absolute values measured at postoperative day 3, they were not affected by tumor- or patient-related factors. Moreover, changes in IL-6 were not affected by the type of surgical approach (robotic or open) or the length or extent of surgery, which further underlies the potential of relative IL-6 determination as an AL biomarker.

There are a number of patient-related factors associated with an increased risk of AL, including diabetes, alcohol, obesity, steroid use, malnutrition, and radiation therapy \[[@cit0032], [@cit0033]\]. Although colorectal surgeons are well versed on this subject, they are still often unable to reliably predict which anastomosis will fail. It is clear that our knowledge on the processes involved in bowel healing is still deficient.

Cytokines act as modulators of inflammatory and immune responses and may also impact the patient's ability to heal. In this study, the analysis of baseline cytokine concentrations showed that lower baseline levels of MCP-1, MIP-1α, IL-8, FGF2, and G-CSF characterized a patient's chance of developing AL. Because FGF2 is a transforming factor, and supports tumor growth, low levels of it may be beneficial for patients from the cancer perspective, although insufficient FGF2 expression may hamper the patient's ability to regenerate the damaged tissues. Still, it is a critical growth factor for fibroblasts and its application has been found useful in surgical wound healing \[[@cit0034]\]. Additionally, the use of exogenous G-CSF, a hematopoietic growth factor, has been shown to be beneficial for accelerated wound healing in clinical studies \[[@cit0035]\]. Similarly, MCP-1, MIP-1α, and IL-8 chemokines are all key players in wound healing, being of particular use during the inflammatory and proliferative phase \[[@cit0036]\]. Thus, low baseline levels of the above-mentioned cytokines may be reflected as deficiencies in the patient's ability to mount a sufficient and timely inflammatory response, as well as subsequent healing of surgical anastomosis.

This study is one of only a few reports to evaluate serum concentrations of cytokines in the early postoperative course following low anterior resections for rectal cancer. The report does have several drawbacks, including the small cohort of 32 patients and, of those, only 5 who developed AL. It should be noted, however, that the study protocol was designed to be small, with the primary goal of gathering information on the potential of serum cytokines as AL predictors. The intent was to do this prior to launching a larger study.

Conclusions {#sec6}
===========

Among 27 different serum cytokines examined on postoperative day 3, hs-CRP was found to have the best diagnostic accuracy when testing for AL. When analyzing relative changes between preoperative and postoperative day 3 cytokine levels, however, relative IL-6 appears to be a better leak predictor than CRP. Additionally, relative IL-6 is not influenced by patient- or tumor-related factors other than AL. Also of note in this study, the cohort of patients with AL presented preoperatively with low levels of MCP-1, MIP-1α, IL-8, FGF2, and G-CSF, which may indicate their reduced ability to heal surgical anastomosis.
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